DK2500436T3 - A method, probe and kit for in situ hybridization of DNA and use thereof - Google Patents
A method, probe and kit for in situ hybridization of DNA and use thereof Download PDFInfo
- Publication number
- DK2500436T3 DK2500436T3 DK11290139.2T DK11290139T DK2500436T3 DK 2500436 T3 DK2500436 T3 DK 2500436T3 DK 11290139 T DK11290139 T DK 11290139T DK 2500436 T3 DK2500436 T3 DK 2500436T3
- Authority
- DK
- Denmark
- Prior art keywords
- mitochondrial
- dna
- probe
- nucleic acid
- seq
- Prior art date
Links
- 239000000523 sample Substances 0.000 title claims description 390
- 238000000034 method Methods 0.000 title claims description 103
- 238000007901 in situ hybridization Methods 0.000 title claims description 16
- 210000004027 cell Anatomy 0.000 claims description 237
- 108020004414 DNA Proteins 0.000 claims description 193
- 230000002438 mitochondrial effect Effects 0.000 claims description 159
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 145
- 150000007523 nucleic acids Chemical group 0.000 claims description 124
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 118
- 230000010076 replication Effects 0.000 claims description 118
- 125000003729 nucleotide group Chemical group 0.000 claims description 97
- 239000002773 nucleotide Substances 0.000 claims description 88
- 102000039446 nucleic acids Human genes 0.000 claims description 71
- 108020004707 nucleic acids Proteins 0.000 claims description 71
- 230000000977 initiatory effect Effects 0.000 claims description 62
- 238000001514 detection method Methods 0.000 claims description 55
- 238000013518 transcription Methods 0.000 claims description 53
- 230000035897 transcription Effects 0.000 claims description 53
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 108091092584 GDNA Proteins 0.000 claims description 38
- 230000000295 complement effect Effects 0.000 claims description 38
- 238000009396 hybridization Methods 0.000 claims description 37
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 30
- 102000053602 DNA Human genes 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 238000000137 annealing Methods 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 16
- 108091064355 mitochondrial RNA Proteins 0.000 claims description 16
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 15
- 208000012268 mitochondrial disease Diseases 0.000 claims description 15
- 229920002866 paraformaldehyde Polymers 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- 229920004890 Triton X-100 Polymers 0.000 claims description 9
- 239000013043 chemical agent Substances 0.000 claims description 9
- 230000008685 targeting Effects 0.000 claims description 8
- 241000972773 Aulopiformes Species 0.000 claims description 6
- 230000003013 cytotoxicity Effects 0.000 claims description 6
- 231100000135 cytotoxicity Toxicity 0.000 claims description 6
- 235000019515 salmon Nutrition 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 108
- 238000002372 labelling Methods 0.000 description 102
- 210000003470 mitochondria Anatomy 0.000 description 101
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 108091060210 Heavy strand Proteins 0.000 description 47
- 239000002953 phosphate buffered saline Substances 0.000 description 43
- 238000002474 experimental method Methods 0.000 description 42
- 230000004543 DNA replication Effects 0.000 description 35
- 238000011282 treatment Methods 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 33
- 230000000875 corresponding effect Effects 0.000 description 32
- 241000282414 Homo sapiens Species 0.000 description 27
- 238000010166 immunofluorescence Methods 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- 238000004925 denaturation Methods 0.000 description 23
- 230000036425 denaturation Effects 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 21
- 210000002950 fibroblast Anatomy 0.000 description 21
- 102100038625 NADH-ubiquinone oxidoreductase chain 1 Human genes 0.000 description 20
- 101710163270 Nuclease Proteins 0.000 description 20
- 238000011529 RT qPCR Methods 0.000 description 19
- 238000012545 processing Methods 0.000 description 19
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 17
- 238000011002 quantification Methods 0.000 description 17
- 102100037173 Mitochondrial-derived peptide MOTS-c Human genes 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 108020004465 16S ribosomal RNA Proteins 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 101001028702 Homo sapiens Mitochondrial-derived peptide MOTS-c Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 230000008045 co-localization Effects 0.000 description 14
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 11
- 239000003298 DNA probe Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000008823 permeabilization Effects 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 108700036248 MT-RNR1 Proteins 0.000 description 10
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 210000003463 organelle Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108020005091 Replication Origin Proteins 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 239000002096 quantum dot Substances 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 230000004065 mitochondrial dysfunction Effects 0.000 description 7
- 230000002914 neoplasic effect Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 101000801530 Homo sapiens Mitochondrial import receptor subunit TOM22 homolog Proteins 0.000 description 6
- 108020004566 Transfer RNA Proteins 0.000 description 6
- 239000012620 biological material Substances 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 102100029344 ATP synthase protein 8 Human genes 0.000 description 5
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 5
- 101000700892 Homo sapiens ATP synthase protein 8 Proteins 0.000 description 5
- 101000835023 Homo sapiens Transcription factor A, mitochondrial Proteins 0.000 description 5
- 102100028386 NADH-ubiquinone oxidoreductase chain 6 Human genes 0.000 description 5
- 102100026155 Transcription factor A, mitochondrial Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 5
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108091093105 Nuclear DNA Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000004898 mitochondrial function Effects 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 101150001086 COB gene Proteins 0.000 description 3
- 108020004394 Complementary RNA Proteins 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 208000005156 Dehydration Diseases 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101150053771 MT-CYB gene Proteins 0.000 description 3
- -1 MgCI2 Chemical compound 0.000 description 3
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 3
- 102100033590 Mitochondrial import receptor subunit TOM22 homolog Human genes 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 101150006264 ctb-1 gene Proteins 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000001215 fluorescent labelling Methods 0.000 description 3
- 239000012909 foetal bovine serum Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 101150088166 mt:Cyt-b gene Proteins 0.000 description 3
- 238000001964 muscle biopsy Methods 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- WNDDWSAHNYBXKY-UHFFFAOYSA-N ATTO 425-2 Chemical compound CC1CC(C)(C)N(CCCC(O)=O)C2=C1C=C1C=C(C(=O)OCC)C(=O)OC1=C2 WNDDWSAHNYBXKY-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 101150090932 ND6 gene Proteins 0.000 description 2
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 2
- 230000008437 mitochondrial biogenesis Effects 0.000 description 2
- 230000030544 mitochondrion distribution Effects 0.000 description 2
- 230000025608 mitochondrion localization Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- PENWAFASUFITRC-UHFFFAOYSA-N 2-(4-chlorophenyl)imidazo[2,1-a]isoquinoline Chemical compound C1=CC(Cl)=CC=C1C1=CN(C=CC=2C3=CC=CC=2)C3=N1 PENWAFASUFITRC-UHFFFAOYSA-N 0.000 description 1
- TXZPMHLMPKIUGK-UHFFFAOYSA-N 2-methoxy-N-(3-methyl-2-oxo-1,4-dihydroquinazolin-6-yl)benzenesulfonamide Chemical compound COC1=CC=CC=C1S(=O)(=O)NC1=CC=C(NC(=O)N(C)C2)C2=C1 TXZPMHLMPKIUGK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000005943 Barth syndrome Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000283705 Capra hircus Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- 241000282670 Cebus albifrons Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100113087 Mus musculus Cgnl1 gene Proteins 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 101150006407 NRF1 gene Proteins 0.000 description 1
- 102000050267 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150012011 PIANP gene Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 241000282576 Pan paniscus Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700184 Rattus sordidus Species 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100294404 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDC36 gene Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001504501 Troglodytes Species 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001955 cumulated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004944 mitochondria-rich cell Anatomy 0.000 description 1
- 230000007631 mitochondrial deficit Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 101150015830 nd1 gene Proteins 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000008689 nuclear function Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000004893 oxazines Chemical class 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11290139.2A EP2500436B1 (en) | 2011-03-17 | 2011-03-17 | Method, probe and kit for DNA in situ hybridation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2500436T3 true DK2500436T3 (en) | 2016-08-29 |
Family
ID=45833435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11290139.2T DK2500436T3 (en) | 2011-03-17 | 2011-03-17 | A method, probe and kit for in situ hybridization of DNA and use thereof |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9957555B2 (enExample) |
| EP (2) | EP2500436B1 (enExample) |
| JP (1) | JP6262533B2 (enExample) |
| DK (1) | DK2500436T3 (enExample) |
| WO (1) | WO2012123588A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3604555B1 (en) | 2011-10-14 | 2024-12-25 | President and Fellows of Harvard College | Sequencing by structure assembly |
| WO2014163886A1 (en) | 2013-03-12 | 2014-10-09 | President And Fellows Of Harvard College | Method of generating a three-dimensional nucleic acid containing matrix |
| ES2991004T3 (es) | 2011-12-22 | 2024-12-02 | Harvard College | Métodos para la detección de analitos |
| EP4491741B1 (en) | 2011-12-22 | 2025-10-15 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
| US9914967B2 (en) | 2012-06-05 | 2018-03-13 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using DNA origami probes |
| SG10201710030QA (en) | 2013-06-04 | 2018-01-30 | Harvard College | Rna-guided transcriptional regulation |
| US10179932B2 (en) | 2014-07-11 | 2019-01-15 | President And Fellows Of Harvard College | Methods for high-throughput labelling and detection of biological features in situ using microscopy |
| WO2017079406A1 (en) * | 2015-11-03 | 2017-05-11 | President And Fellows Of Harvard College | Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix |
| WO2017100343A1 (en) | 2015-12-07 | 2017-06-15 | Arc Bio, Llc | Methods and compositions for the making and using of guide nucleic acids |
| AU2017257624B2 (en) | 2016-04-25 | 2023-05-25 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
| GB2569252A (en) | 2016-08-31 | 2019-06-12 | Harvard College | Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing |
| JP7239465B2 (ja) | 2016-08-31 | 2023-03-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 蛍光ｉｎ ｓｉｔｕ配列決定による検出のための核酸配列ライブラリの作製法 |
| US11185568B2 (en) | 2017-04-14 | 2021-11-30 | President And Fellows Of Harvard College | Methods for generation of cell-derived microfilament network |
| EP4741512A2 (en) | 2017-09-22 | 2026-05-13 | University of Washington | In situ combinatorial labeling of cellular molecules |
| EP3836967A4 (en) | 2018-07-30 | 2022-06-15 | ReadCoor, LLC | METHODS AND SYSTEMS FOR SAMPLE PROCESSING OR ANALYSIS |
| WO2020076976A1 (en) | 2018-10-10 | 2020-04-16 | Readcoor, Inc. | Three-dimensional spatial molecular indexing |
| CN115362264A (zh) | 2020-01-29 | 2022-11-18 | 10X基因组学有限公司 | 用于分析物检测的组合物和方法 |
| US20220049303A1 (en) | 2020-08-17 | 2022-02-17 | Readcoor, Llc | Methods and systems for spatial mapping of genetic variants |
| CN114891861B (zh) * | 2022-05-05 | 2024-07-26 | 江苏省食品药品监督检验研究院 | 一种检测抗体中cho细胞残留dna的raa试剂盒及其检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541308A (en) * | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| WO2000061819A2 (en) * | 1999-04-14 | 2000-10-19 | California Institute Of Technology | Methods of detection and modulation of age-related mutations |
| US20070190534A1 (en) | 2001-06-11 | 2007-08-16 | Genesis Genomics Inc. | Mitochondrial sites and genes associated with prostate cancer |
| USH2220H1 (en) * | 2001-08-10 | 2008-07-01 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| US20070203083A1 (en) * | 2003-06-13 | 2007-08-30 | Mootha Vamsi K | Methods Of Regulating Metabolism And Mitochondrial Function |
| JP2005107404A (ja) | 2003-10-01 | 2005-04-21 | Matsushita Electric Ind Co Ltd | 広角撮像光学系、並びにそれを備えた広角撮像装置、監視用撮像装置、車載用撮像装置及び投写装置 |
-
2011
- 2011-03-17 DK DK11290139.2T patent/DK2500436T3/en active
- 2011-03-17 EP EP11290139.2A patent/EP2500436B1/en not_active Not-in-force
-
2012
- 2012-03-16 EP EP12708876.3A patent/EP2686440B1/en not_active Not-in-force
- 2012-03-16 JP JP2013558467A patent/JP6262533B2/ja not_active Expired - Fee Related
- 2012-03-16 US US14/005,364 patent/US9957555B2/en active Active
- 2012-03-16 WO PCT/EP2012/054739 patent/WO2012123588A1/en not_active Ceased
-
2018
- 2018-04-27 US US15/965,681 patent/US11566280B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2500436B1 (en) | 2016-05-25 |
| US9957555B2 (en) | 2018-05-01 |
| JP2014509862A (ja) | 2014-04-24 |
| JP6262533B2 (ja) | 2018-01-17 |
| US20140087378A1 (en) | 2014-03-27 |
| US20190330691A1 (en) | 2019-10-31 |
| EP2500436A1 (en) | 2012-09-19 |
| EP2686440A1 (en) | 2014-01-22 |
| EP2686440B1 (en) | 2017-12-20 |
| WO2012123588A1 (en) | 2012-09-20 |
| US11566280B2 (en) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2500436B1 (en) | Method, probe and kit for DNA in situ hybridation and use thereof | |
| US20250263784A1 (en) | Multiplex labeling of molecules by sequential hybridization barcoding | |
| US20220026433A1 (en) | Cleavable fluorescent tyramide for sensitive and multiplexed analysis of biological samples | |
| US20210115504A1 (en) | Multiplex labeling of molecules by sequential hybridization barcoding with rapid switching and rehybridization of probes | |
| AU2014268710B2 (en) | Transposition into native chromatin for personal epigenomics | |
| Nuovo et al. | A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets | |
| CN105612261B (zh) | 作为生物标记物的miRNA-124 | |
| Dodel et al. | TREX reveals proteins that bind to specific RNA regions in living cells | |
| CA2840558C (en) | Methods of detecting gene fusions using first and second nucleic acid probes | |
| JP2011511949A5 (enExample) | ||
| JP6247934B2 (ja) | 単一細胞において染色体構造および遺伝子発現を同時に検出するための方法 | |
| CN102732619B (zh) | 一种miRNA的原位杂交探针及其检测试剂盒和应用 | |
| CN114945681A (zh) | 用于连续核酸检测的方法 | |
| Ling et al. | Technical innovations of signal amplification in fluorescence in situ hybridization | |
| KR20220035958A (ko) | 표적 분석에 관한 방법 및 조성물 | |
| Class et al. | Patent application title: METHOD, PROBE AND KIT FOR DNA IN SITU HYBRIDIZATION AND USE THEREOF | |
| CN113025690B (zh) | 一种核酸探针组及其应用 | |
| US20160145686A1 (en) | Biomarker for senescence and use thereof | |
| Hansen et al. | Transcription arrest induces formation of protective RNA granules in mitochondria | |
| Hansen et al. | Transcription arrest induces formation of RNA granules in mitochondria | |
| KR102224910B1 (ko) | Rna 은 제자리 혼성화 방법을 통한 aimp2-dx2 신호 자동화 검출 방법 | |
| Li et al. | Integration of Demethylation-Switchable Deoxyribozyme with Controllable Self-Assembly of Branched DNA Nanostructures Enables In Situ Monitoring of FTO Demethylation in Living Cells | |
| WO2022248889A1 (en) | Assays | |
| Smolina | Application of PNA Openers for Fluorescence-Based Detection of Bacterial DNA | |
| Bäumer | Functional genetic analysis of motor neuron disease |